X7c156f05.aaca.4c79.bdb2.94044d5422e8
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 83
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.480
- UNFOLDED_PROTEIN_RESPONSE+0.410
- OXIDATIVE_PHOSPHORYLATION+0.370
- PROTEIN_SECRETION+0.370
- INTERFERON_GAMMA_RESPONSE+0.350
- MYC_TARGETS_V1+0.340
- DNA_REPAIR+0.200
- ANGIOGENESIS+0.190
- MTORC1_SIGNALING+0.180
- MYC_TARGETS_V2+0.120
Top 10 suppressed
- APICAL_SURFACE-0.360
- WNT_BETA_CATENIN_SIGNALING-0.360
- ESTROGEN_RESPONSE_EARLY-0.300
- MITOTIC_SPINDLE-0.300
- IL2_STAT5_SIGNALING-0.280
- HEDGEHOG_SIGNALING-0.230
- HYPOXIA-0.230
- TNFA_SIGNALING_VIA_NFKB-0.220
- G2M_CHECKPOINT-0.210
- KRAS_SIGNALING_DN-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CZ3NA7KV | Supratentorial Ependymoma | — | 0.796 |
| 2 | TCGA-A8-A06T-01A-11R-A00Z-07 | — | B | 0.779 |
| 3 | MNG85 | — | — | 0.742 |
| 4 | C3N-01415 | — | cohortA1 | 0.724 |
| 5 | TCGA-CV-6954-01A-11R-1915-07 | — | — | 0.723 |
| 6 | BS_CZ3ER8DY | Supratentorial Ependymoma | — | 0.717 |
| 7 | s0102864 | — | — | 0.717 |
| 8 | BS_MT15SGJN | Supratentorial Ependymoma | — | 0.712 |
| 9 | SRR27320678 | — | — | 0.706 |
| 10 | SRR6013584 | — | cohortA1 | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |